ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,149.69
0.07%
Dow Jones
37,815.92
-1.49%
Gold vs US Dollar
2,290.49
-0.05%
Brent Oil
85.165
-0.85%
Bitcoin
57,240.09
-5.54%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Medivir Ab (0GP7)

  7. Medivir Ab (0GP7) News

Medivir Ab (0GP7)

Medivir Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0GP7
DateTimeSourceHeadlineSymbolCompany
15/01/202407:45PR Newswire (US)Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostroxLSE:0GP7Medivir Ab
04/01/202407:47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyLSE:0GP7Medivir Ab
19/12/202307:54PR Newswire (US)Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development planLSE:0GP7Medivir Ab
13/12/202310:12PR Newswire (US)Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approvalLSE:0GP7Medivir Ab
06/12/202311:20PR Newswire (US)Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runwayLSE:0GP7Medivir Ab
06/12/202307:44PR Newswire (US)Medivir to present at the Carlsquare Equity Research Investor DayLSE:0GP7Medivir Ab
01/12/202310:32PR Newswire (US)Bulletin from Extraordinary General Meeting in Medivir AB (publ)LSE:0GP7Medivir Ab
27/11/202308:52PR Newswire (US)Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCCLSE:0GP7Medivir Ab
22/11/202307:46PR Newswire (US)Medivir to present at the Redeye Life Science DayLSE:0GP7Medivir Ab
21/11/202307:48PR Newswire (US)Medivir to present at the Erik Penser Bank Company EventLSE:0GP7Medivir Ab
13/11/202308:49PR Newswire (US)Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDALSE:0GP7Medivir Ab
07/11/202320:50PR Newswire (US)Notice of Extraordinary General Meeting in Medivir AB (publ)LSE:0GP7Medivir Ab
27/10/202308:01PR Newswire (US)MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023LSE:0GP7Medivir Ab
25/10/202307:46PR Newswire (US)Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on FridayLSE:0GP7Medivir Ab
23/10/202307:48PR Newswire (US)Nomination Committee of Medivir appointedLSE:0GP7Medivir Ab
20/10/202314:29PR Newswire (US)Change in Medivir's Board of DirectorsLSE:0GP7Medivir Ab
16/05/202317:38PR Newswire (US)Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023LSE:0GP7Medivir Ab
04/05/202315:55PR Newswire (US)Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)LSE:0GP7Medivir Ab
04/05/202315:25PR Newswire (US)Resolutions at the Annual General Meeting in Medivir on 4 May 2023LSE:0GP7Medivir Ab
27/04/202308:06PR Newswire (US)MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023LSE:0GP7Medivir Ab
17/04/202308:30PR Newswire (US)Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combinationLSE:0GP7Medivir Ab
04/04/202310:03PR Newswire (US)Medivir 2022 Annual Report publishedLSE:0GP7Medivir Ab
31/03/202311:25PR Newswire (US)Notice of Annual General Meeting of Medivir AB (publ)LSE:0GP7Medivir Ab
17/03/202308:01PR Newswire (US)Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACRLSE:0GP7Medivir Ab
14/03/202308:18PR Newswire (US)First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®LSE:0GP7Medivir Ab
08/03/202315:08PR Newswire (US)Medivir to present at the Stockholm Corporate Finance Life Science DayLSE:0GP7Medivir Ab
23/02/202308:03PR Newswire (US)Medivir to present at the Erik Penser Bank Healthcare DayLSE:0GP7Medivir Ab
21/02/202308:54PR Newswire (US)Pia Baumann takes up her position as Chief Medical OfficerLSE:0GP7Medivir Ab
20/02/202310:04PR Newswire (US)Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCCLSE:0GP7Medivir Ab
15/02/202308:15PR Newswire (US)MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2022LSE:0GP7Medivir Ab
 Showing the most relevant articles for your search:LSE:0GP7

Your Recent History

LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
SCLP
Scancell
LSE
TERN
Tern
LSE
TXP
Touchstone Exploration
LSE
TRIN
Trinity Exploration & Pr...
LSE
CHLL
Chill Brands
LSE
AAZ
Anglo Asian Mining
LSE
AAU
Ariana Resources
LSE
SOLG
Solgold
LSE
GFM
Griffin Mining
LSE
ALGW
Alpha Growth
LSE
GCM
Gcm Resources
LSE
POS
Plexus
LSE
GSF
Gore Street Energy Storage
LSE
PANR
Pantheon Resources
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved